

# Evolution of ICH - how the implementation of ICH guidelines in the EAEU region can be supported

Dr. Petra Doerr  
Director  
Petra Doerr Consulting  
GmbH



DIA

# Disclaimer

The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to DIA, its directors, officers, employees, volunteers, members, chapters, councils, communities or affiliates, or any organization with which the presenter is employed or affiliated.

These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. DIA and the DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.

# Disclosure Statement

- ☒ I have no real or apparent relevant financial relationships to disclose  
☐ I am employed by a regulatory agency, and have nothing to disclose

*Please note that DIA is not requesting a numerical amount to be entered for any disclosure, please indicate by marking the check box, and then providing the company name only for those disclosures you may have*

Type of Financial Interest within last 12 months		Name of Commercial Interest
<input type="checkbox"/>	Grants/Research Funding	
<input type="checkbox"/>	Stock Shareholder	
<input type="checkbox"/>	Consulting Fees	
<input type="checkbox"/>	Employee	
<input type="checkbox"/>	Other (Receipt of Intellectual Property Rights/Patent Holder, Speaker's Bureau)	

Will any of the relationships reported in the chart above impact your ability to present an unbiased presentation? ☐ Yes ☐ No

**In accordance with the ACPE requirements, if the disclosure statement is not completed or returned, participation in this activity will be refused.**

# Outline



## Introduction



## Evolution of ICH



## ICH Guideline Implementation



## Summary & Conclusion



# Introduction



## International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)

- Unique harmonisation initiative for regulators and pharmaceutical industry
- Originally founded in 1990
- Established as a non-profit legal entity under Swiss Law on 23 October 2015



## ICH Vision

The vision of ICH is to promote public health through international harmonisation of technical requirements that contributes to the

- ▶ timely introduction of new medicines and continued availability of the approved medicines to patients,
- ▶ prevention of unnecessary duplication of clinical trials in humans,
- ▶ development, manufacturing and registration of safe, effective and high quality medicines, and
- ▶ minimisation of the use of animal testing without compromising safety and effectiveness.



## Over 60 guidelines on technical requirements

**Quality: 23**    **Safety: 14**    **Efficacy: 20**  
**Multidisciplinary: 5**



### Quality Guidelines

Harmonisation achievements in the Quality area include pivotal milestones such as the conduct of stability studies, defining relevant thresholds for impurities testing and a more flexible approach to pharmaceutical quality based on Good Manufacturing Practice (GMP) risk management.



### Safety Guidelines

ICH has produced a comprehensive set of safety Guidelines to uncover potential risks like carcinogenicity, genotoxicity and reprotoxicity. A recent breakthrough has been a non-clinical testing strategy for assessing the QT interval prolongation liability; the single most important cause of drug withdrawals in recent years.



### Efficacy Guidelines

The work carried out by ICH under the Efficacy heading is concerned with the design, conduct, safety and reporting of clinical trials. It also covers novel types of medicines derived from biotechnological processes and the use of pharmacogenetics/genomics techniques to produce better targeted medicines.



### Multidisciplinary Guidelines

Those are the cross-cutting topics which do not fit uniquely into one of the Quality, Safety and Efficacy categories. It includes the ICH medical terminology (MedDRA), the Common Technical Document (CTD) and the development of Electronic Standards for the Transfer of Regulatory Information (ESTRI).

<https://www.ich.org/products/guidelines.html>





## Steps in the ICH process





# Evolution of ICH



## ICH Reform

- ✓ **Governance:** Focus the role of regulators in ICH and further distinguish decision-making role of regulators vs. regulated industry
- ✓ **Transparency:** Improve transparency and openness of ICH and its processes
- ✓ **International outreach:** Increase the involvement of other regulators as well as global industry sectors affected by ICH guidelines
- ✓ **Legal entity:** Set up ICH as a legal entity as continuing activities in the current informal setting will be difficult in the changed environment
- ✓ **Funding:** Identify an alternative funding model that would make ICH less dependent of industry funding

# Evolution of ICH



## Structure of the ICH Association

Management Committee

Assembly

Auditors

MedDRA Management Committee

ICH Secretariat

WG

WG

WG



## Remit of Assembly and Management Committee

- ▶ The **Assembly** is the overarching body of the Association, composed of all Members that takes decisions, regarding Articles of Association, Rules of Procedures, admission of new Members, adoption of ICH Guidelines, etc.
- ▶ The **Management Committee** is the body that oversees operational aspects of the Association on behalf of all members, including administrative and financial matters and oversight of the WGs.



## Assembly Members and Observers

16 members

32 observers

- ▶ **Members:**
  - Founding Regulatory: EC/EMA, MHLW/PMDA
  - Founding Industry: EFPIA, JPMA, PhRMA
  - Standing Regulatory: Health Canada, Swissmedic
  - Regulatory: ANVISA (Brazil), NMPA (China),  
TFDA (Chinese Taipei), HSA  
(Singapore) MFDS (South Korea)
  - Industry: BIO, IGBA, Global Self-Care  
Federation
- ▶ **Standing Observers:** WHO, IFPMA
- ▶ **Observers:** Regulatory authorities, RHIs,  
international pharmaceutical industry  
organisations and international organisations  
with an interest in pharmaceuticals



## Assembly Members and Observers

- ▶ **Regulatory authorities:** SCDMTE, Armenia; TGA, Australia; INVIMA, Colombia; CECMED, Cuba; CDSCO, India; NRA, Iran; National Center, Kazakhstan; NPRA, Malaysia; COFEPRIS, Mexico; MMDA, Moldova; Roszdravnadzor, Russia; SAHPRA, South Africa; TITCK, Turkey; **NEW as of June 2019:** ANMAT, Argentina; CPED, Israel; JFDA, Jordan; SFDA, Saudi Arabia
- ▶ **Regional Harmonisation Initiatives (RHIs):** APEC, ASEAN, EAC, GHC, PANDRH, SADC
- ▶ **International organisations with an interest in pharmaceuticals:** BMGF, CIOMS, EDQM, IPEC, PDIA, WHO



## Enlarged membership of the Management Committee

### Members:

- Founding Regulatory: EC/EMA, MHLW/PMDA, US-FDA
- Founding Industry: EFPIA, JPMA, PhRMA
- Standing Regulatory: Health Canada, Swissmedic
- Regulatory: NMPA (China), HSA  
(th Korea)
- Industry:


**Standing Observers:** WHO, IFPMA



# Evolution of ICH

## Experts in ICH Working Groups

As of May 2019, 39 % of the 646 experts in ICH Working Groups came from members, observers and standing observers (March 2017: 24 %, November 2018: 34 %).



- Founding/Standing Member: 395 = 61%
- Member: 181 = 28%
- Observer: 48 = 7%
- Standing Observer: 17 = 3%
- Other: 5 = 1%



## Current focus

The ICH Management Committee is working to:

- Manage the size of the Expert Working Groups due to the increasing membership in ICH.
- Ensure adequate implementation of ICH guidelines in a harmonised manner by all Regulatory Members considering that the notion of implementation is not always understood in the same way.
- Increase the resources on training activities. There are multiple work streams ongoing with a focus on engaging with training organisations and institutions to assist ICH in this activity.



# ICH Guideline Implementation

# Implementation of ICH Guidelines




- ▶ ICH Implementation Subcommittee established in Nov. 2017
- ▶ Mandate: Build an implementation survey to provide transparency and identify training opportunities
- ▶ Long-term objective: establish a sustainable ICH-driven mechanism to assess implementation of the ICH Guidelines over time.

# Implementation of ICH Guidelines




## Definitions: (Initial) **Implementation** of ICH Guidelines



# Implementation of ICH Guidelines



## Definitions: **Adherence** to ICH Guidelines (in practice)



# Implementation of ICH Guidelines



## Definitions of terms around “implementation”

▶ <https://www.ich.org/products/ich-guidelines-implementation.html>

The screenshot shows the ICH website's 'ICH Guidelines Implementation' page. The header features the ICH logo with the tagline 'harmonisation for better health' and navigation links for 'Contact' and 'Log In'. Below the header is a menu bar with links for 'Home', 'About ICH', 'Work Products', 'Meetings', 'Training', 'Newsroom', and social media icons. The main content area is titled 'ICH Guidelines Implementation / Work Products' and contains the following text:

At Step 5 of the ICH process, harmonised ICH Guidelines are implemented by ICH Regulatory Members and Observers within their respective country/region. This is in line with the ICH Articles of Association and the aim and intention that all ICH Regulatory Members should implement all ICH Guidelines. For ICH Regulatory Observers, implementation of (certain) ICH Guidelines is a pre-requisite to become an ICH Regulatory Member.

ICH Guidelines are implemented in accordance with the applicable national/local/regional rules, with the stage of implementation of all ICH Guidelines also being dependent on when a Member or Observer has joined ICH.

Information on ICH Guideline implementation for Founding and Standing Regulatory Members is currently published on the ICH website [www.ich.org](http://www.ich.org) under each ICH Guideline section. Information on ICH Guideline implementation by newer Regulatory Members and Observers will be made available shortly.

**Understanding Implementation of ICH Guidelines**

Monitoring the progress of international harmonisation and coordinating efforts in this regard is an important ICH focus. ICH is currently working to understand the level of implementation and adherence to ICH Guidelines within Regulatory Member and Observer countries/regions. An ICH-driven independent third party survey is being conducted in support of this effort. Furthermore, recognising the need to have a common view on different degrees of implementation, ICH has also developed [Definitions of terms in the context of the implementation of ICH Guidelines](#).

On the right side of the page, there is a 'Related Links' section with a link to 'ICH Implementation Definitions' and an image of two interlocking rings.



## Survey on adequacy of implementation and adherence

- ▶ Survey with one questionnaire addressing both adequacy of implementation and adherence was conducted in 1<sup>st</sup> half of 2019.
- ▶ Results have been presented to the ICH Assembly in June 2019.
- ▶ A summary report will be made public before the end of 2019.
- ▶ The implementation subcommittee has completed its mandate and has been disbanded.





## Who are the „New members“?

- “Old” regulatory members: EC/EMA (EU), US-FDA, PMDA/MHLW, Health Canada, Swissmedic
- “New(er)” regulatory members:
  - DRAs and DOHs involved in the Global Cooperation Group since 1999 (e.g. TFDA, Chinese Taipei; MFDS, Korea; HSA, Singapore; ...)
  - Other RAs: NMPA, China; ANVISA, Brazil; ...
- Regulatory Observers (are also required to implement certain ICH guidelines if they want



## Challenges for new members and observers

- ▶ Not having participated in guideline development may result in higher risk of misinterpretation
- ▶ (Local) industry not yet familiar/adjusted to international guidelines
- ▶ In order to make ICH guidelines more binding on industry, they are incorporated in regulations – which makes initial implementation and adaptations in case of revisions more time-consuming/laborious
- ▶ Language/translation



## Challenges for new members and observers

- ▶ High training needs
- ▶ Need to decide which guidelines are most relevant; cannot implement all guidelines at the same time.  
“Old” members have implemented over time (almost 30 years!).
- ▶ “Electronic guidelines”: additional challenges due to need for developing and implementing IT-systems (complexity, cost); question of “implementability”: is industry ready?




# Summary & Conclusions

# Summary & Conclusions



- ICH has substantially grown its geographic outreach following the recent reform.
- Participation of new members and observers in guideline development is increasing.
- By addressing issues relating to the implementation of ICH guidelines, training activities can be better targeted with a view to achieving a harmonised implementation amongst all ICH Regulatory Members (and Observers).
- In line with its mission, ICH continues to achieve international harmonisation through technical guidelines which now have broader outreach due to the increased member- and observership.



Thank you for  
your attention!  
Questions?

# List of abbreviations (in alphabetical order)

ANMAT	National Administration for Drugs, Food and Medical Devices	ICH	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
ANVISA	Brazilian Health Surveillance Agency	IFPMA	International Federation of Pharmaceutical Manufacturers & Associations
APEC	Asia-Pacific Economic Cooperation	IGBA	International Generic and Biosimilar Medicines Association
APIC	Active Pharmaceutical Ingredients Committee	INVIMA	National Institute of Food and Drug Monitoring, Columbia
ASEAN	Association of Southeast Asian Nations	JFDA	Jordan Food and Drug Administration
BIO	Biotechnology Innovation Organization	JPMA	Japan Pharmaceutical Manufacturers Association
BMGF	Bill & Melinda Gates Foundation	MedDRA	Medical dictionary for adverse event reporting and coding of clinical trial data
CDSCO	Central Drugs Standard Control Organization, India	MFDS	Ministry of Food and Drug Safety, Korea
CECMED	Regulatory Authority for Medicines and Medical Devices, Cuba	MHLW	Ministry of Health, Labour and Welfare, Japan
CIOMS	Council for International Organizations of Medical Sciences	MMDA	Medicines and Medical Devices Agency, Moldova
COFEPRIS	Federal Commission for the Protection against Sanitary Risk, Mexico	NMPA	National Medical Products Administration, China
CPED	Center for Pharmaceuticals and Enforcement Divisions, Israel	NPRA	National Pharmaceutical Regulatory Agency, Malaysia
EAC	East African Community	NRA	National Regulatory Authority
EC	European Commission	PANDRH	Pan-American Network for Regulatory Harmonisation
EDQM	European Directorate for the Quality of Medicines and Healthcare		
EFPIA	European Federation of Pharmaceutical Industries and Associations		
EMA	European Medicines Agency		
FPP	Finished Pharmaceutical Product		
GBT	Global Benchmarking Tool, WHO		
GHC	Gulf Health Council		

## List of abbreviations (in alphabetical order)

PhRMA	Pharmaceutical Research and Manufacturers of America
PIC/S	Pharmaceutical Inspections Cooperation Scheme
PMDA	Pharmaceuticals and Medical Devices Agency, Japan
RHI	Regional Harmonisation Initiative
Roszdraznavor	Federal Service on Surveillance in Healthcare, Russia
SADC	Southern African Development Community
SAHPRA	South African Health Products Regulatory Authority
SCDMTE	Scientific Center of Drug and Medical Technologies Expertise, Armenia
SFDA	Saudi Food and Drug Authority, Saudi Arabia
TFDA	Taiwan Food and Drug Administration
TGA	Therapeutic Goods Administration, Australia
TITCK	Turkish Medicines and Medical Devices Agency
US-FDA	United States Food and Drug Administration
USP	United States Pharmacopeia
WG	Working Group
WHO	World Health Organisation